-- Robert Preidt
WEDNESDAY, Jan. 9 (HealthDay News) -- The risks of breast and
colon cancer screening likely outweigh the benefits for people with
a life expectancy of less than 10 years, according to a new
However, the researchers emphasized that the results should not
be used to deny screening for patients with a shorter life
expectancy, but rather to help doctors and patients make informed
decisions about screening.
For the study, Sei Lee, assistant professor of medicine in the
division of geriatrics at University of California, San Francisco,
and colleagues analyzed the findings of five breast cancer and four
colon cancer screening trials involving patients aged 50 and older.
The studies were published between 1986 and 2008 and ranged in size
from a little less than 40,000 people to more than 150,000 people.
Follow-up of patients ranged from eight to 20 years.
Over five years, an average of 2.8 colon cancer deaths were
prevented for every 10,000 people screened. However, this benefit
increased with longer follow-up. Over 15 years, 23 colon cancer
deaths were prevented for every 10,000 people screened, the
In addition, the researchers found that over five years, an
average of 5.1 breast cancer deaths were prevented for every 10,000
women screened. Over 15 years, 19 breast cancer deaths were
prevented for every 10,000 women screened, they noted.
According to the study, published online Jan. 8 in the
BMJ, it took an average of 4.8 years to prevent one colon
cancer death for every 5,000 people screened and 10.3 years to
prevent one death for every 1,000 people screened. It took an
average of three years to prevent one breast cancer death for every
5,000 women screened and 10.7 years to prevent one death for every
1,000 women screened.
Based on their findings, the study authors suggest that people
with a life expectancy of more than 10 years should be encouraged
to undergo colon and breast cancer screening, while those with a
life expectancy of three to five years "probably should be
discouraged from screening since the potential risks likely
outweigh the very small probability of benefit."
Those risks include false positive results, which might lead to
unnecessary treatment, Lee and colleagues said in a journal news
The U.S. National Cancer Institute has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.